Multispectral Optoacoustic Tomography (MSOT) of human brown adipose tissue and skeletal muscle

人体棕色脂肪组织和骨骼肌组成和代谢过程的光声成像是我们研究单位必不可少的核心资产。因此，我们申请便携式手持式多光谱光声断层扫描（MSOT）装置。该装置将被定制，通过增加MSOT的穿透深度和灵敏度来重新设计和改进代谢的光声成像。MSOT单元将用于P2和P5的中试人体研究以及FatCalEx研究（P6）。它为人体代谢过程的静态和动态评估提供了一种快速、无标签、安全和通用的成像方式。在选定的靶组织中，MSOT将能够实时成像局部组成、氧化代谢、血管化和脂质运输的变化。RU5298的研究将应用这种光声成像方式来监测基线的代谢过程，并响应急性代谢挑战，如冷暴露、试餐和运动。我们期望在这些反应中看到很大的个体差异，以及肥胖人群代谢灵活性受损。根据MSOT的评估，热量限制干预，无论是单独的，还是与运动相结合，都可能在不同程度上重建代谢灵活性。这提供了一种迄今为止未见的成像方式来观察局部组织反应的个体差异和可塑性。我们期望我们的人体研究将揭示肥胖人群代谢紊乱的新生物标志物。这些生物标记物将对肥胖症治疗中新的个性化干预措施的发展具有诊断价值。

Optoacoustic imaging of composition and metabolic processes in human brown adipose tissue and skeletal muscle is a core asset essential for our research unit. We therefore apply for a portable handheld Multispectral Optoacoustic Tomography (MSOT) unit. This device will be customized to redesign and improve the optoacoustic imaging of metabolism by increasing the penetration depth and sensitivity of MSOT. The MSOT unit will be used to capacity in pilot human studies of P2 and P5, and in the FatCalEx study (P6). It provides a fast, label-free, safe and versatile imaging modality for the static and dynamic assessment of metabolic processes in humans. In the selected target tissues, MSOT will enable real-time imaging of local changes in composition, oxidative metabolism, vascularization, and lipid transport. Research in RU5298 will apply this optoacoustic imaging modality to monitor metabolic processes at baseline, and in response to acute metabolic challenges, such as cold exposure, test meals, and exercise. We expect to see large inter-individual variability in these responses, and impaired metabolic flexibility in people with obesity. Caloric restriction intervention, either alone, or combined with exercise, may to variable degree reconstitute metabolic flexibility, as assessed by MSOT. This offers a so far unseen imaging modality to observe individual variation and plasticity in local tissue responses. We expect that our human studies will reveal novel biomarkers for the metabolic derangements in people with obesity. These biomarkers will be of diagnostic value for the development of new personalized interventions in the treatment of obesity.